This report is required built	7 1100 04 (0) 5-11			are		Antipipatentic Al-Content		And the second design of the second design of the	
This report is required by la result in an order to cease	and desist and to be subject	t to penalties as provided	egulations can for in Section 2	150.	See reverse additional in		Interagency F 0180-DOA-A	Report Control No	
UNITED STATES DEPARTMENT OF AGRICULTURE ANIMAL AND PLANT HEALTH INSPECTION SERVICE				1. REGISTRA 23-R-0061		CUSTOMER NO. 352	FORM APPROVED OMB NO. 0579-0036		
ANNUAL REP	ORT OF RESE	EARCH FACT	ITY	2. HEADQUAR	RTERS RESE	ARCH FACILITY (Name and	d Address, as reg	istered with USDA,	
(TYPE OR PRINT) 3. REPORTING FACILITY (List all locations where animals were housed or used in actual research sheets if necessary.)				include Zip Code) MILLENNIUM BIORESEARCH INC 1765 WENTZ ROAD P.O. BOX 178 SPINNERSTOWN, PA 18967 (215) 536-4110					
sheets if necessary.)	an occurrent where animals	s were noused or used in	actual research	, testing, teaching	, or experimer	itation, or held for these pur	poses. Attach add	ditional	
See Attached Listing		F	ACILITY LOCA	TIONS(sites)			1/17	101	
						······································	2 4 2006	an a	
REPORT OF ANIMALS USED B	Y OR UNDER CONTROL C	F RESEARCH FACILITY	r (Attach addition	nal sheets if nece.	ssary or use A	PHIS FORM 7023A )			
A. Animals Covered By The Animal Welfare Regulations	B. Number of animals being bred, conditioned, or held for use in teaching, testing, experiments, research, or surgery but not yet used for such purposes	C. Number of animals upon which teaching, research, experiments, or tests were conducted involving no pain, distress, or use of pain- relieving drugs.	D. Number of animals upon which experiments, teaching, research, surgery, or tests were conducted involving accompanying pain or distress to the animals and for which appropriate anesthetic, analgesic, or tranguilizing drugs were used.		E. Number of animals upon which teaching, experiments, research, surgery or tests were conducted involving accompanying pain or distress to the animals and for which the use of appropriate anesthetic,analgesic, or tranguilizing drugs would have adversely affected the procedures, results, or interpretation of the teaching, research, experiments, surgery, or tests. (An explanation of the procedures producing pain or distress in these animals and the reasons such drugs were not used must be attached to this report)		F TOTAL NO. OF ANIMALS (Cols. C + D + E)		
4. Dogs					- must be	anached to this report)			
5. Cats									
6. Guinea Pigs	8	813	0		464			1277	
7. Hamsters		24	0		0			24	
8. Rabbits	68	764		1	254			1019	
9. Non-Human Primates									
10. Sheep									
11. Pigs									
12. Other Farm Animals									
13. Other Animals									
Ferrets	4	0		0		0		0	
ASSURANCE STATEMENTS					1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.		l		
<ol> <li>Professionally accentable st</li> </ol>	andarda aquercian the	the second se	the second s	the second s				and the second se	

Professionally acceptable standards governing the care, treatment, and use of animals, including appropriate use of anesthetic, analgesic, and tranquilizing drugs, prior to, during, and following actual research, teaching, testing, surgery, or experimentation were followed by this research facility.

2) Each principal investigator has considered alternatives to painful procedures.

3) This facility is adhering to the standards and regulations under the Act, and it has required that exceptions to the standards and regulations be specified and explained by the principal investigator and approved by the Institutional Animal Care and Use Committee (IACUC). A summary of all the exceptions is attached to this annual report. In addition to identifying the IACUC-approved exceptions, this summary includes a brief explanation of the exceptions, as well as the species and number of animals affected.

4) The attending veterinarian for this research facility has appropriate authority to ensure the provision of adequate veterinary care and to oversee the adequacy of other aspects of animal care and use.

## CERTIFICATION BY HEADQUARTERS RESEARCH FACILITY OFFICIAL (Chief Executive Officer or Legally Responsible Institutional official) I certify that the above is true, correct, and complete (7 U.S.C. Section 2143)

(b)(6), (b)(7)(c)

DATE SIGNED

1121-06

- HEADQUARTERS

Gan

(AUG 91)

SIGNATIONE OF CEO

## **MB Research Laboratories**

1765 wentz road, p. o. box 178 spinnerstown, pa 18968 phone (215) 536-4110 fax (215) 536-1816 office@mbresearch.com

NOV 2 4 2006 COLUMN E EXPLANATION - 2006

Facility Registration No: 23-R-0061

**Guinea Pigs**: The four hundred sixty-four guinea pigs listed in Column E were used on Magnusson-Kligman sensitization evaluations, as described in OECD testing guideline regulations. The Magnusson-Kligman is the favored guinea pig sensitization assay in Europe over the less invasive Buehler method and is used by sponsors pursuing a global market for their product. The purpose of this study is to assess the sensitization potential of a substance following repeated dermal exposure. The initial inductions used for these studies involve the use of Freund's Complete Adjuvant injections which produce an irritant response. This is a regulatory driven protocol and there are no provisions in the test guideline to permit the use of analgesia or anesthetics. The citing for this test guideline is as follows:

 Organization for Economic Cooperation and Development (OECD) Guidelines for Testing of Chemicals, Guideline #406, Skin Sensitization, Adopted by the Council on July 17, 1992.

Currently, the Local Lymph Node Assay (LLNA) using mice is an accepted method for sensitization studies. However, this study requires the radioactive procedures. In 2002, MB was awarded a Small Business Innovative Research (SBIR) Phase II grant for the development and commercialization of a Local Lymph Node Assay using mice but eliminating the need for radioactive procedures. This Phase II research has been successfully completed. MB Research is currently conducting these studies for commercial clients. However, the regulatory agencies, i.e., FHSA, EPA, OECD, have not yet adopted this LLNA version as an approved test guideline for sensitization studies, so it cannot be used as an alternative to either the Magnusson-Kligman or Buehler Methods.

**Rabbits**: The two hundred fifty-four rabbits listed in Section E of the Annual Report were used in EPA, OECD or FHSA dermal or ocular irritation/corrosion studies and dermal toxicity studies in which the use of anesthetics has the potential to mask or worsen the responses being investigated. The purpose of these studies is to determine the irritant or corrosive effect of a substance when applied to the skin or eye. In cases where there is reason to believe that ocular or dermal reactions may be severe, MB recommends to the study sponsor that only one rabbit be tested. In cases where the reaction is severe, the sponsor is notified and the animals are humanely sacrificed to avoid further distress. The citings for these studies are as follows:

- OECD Guidelines for Testing of Chemicals:
  - Guideline #402, Acute Dermal Toxicity in Rabbits, Adopted February 24, 1987
  - o Guideline #404, Acute Dermal Irritation/Corrosion, Adopted by the Council April 2002
  - o Guideline #405, Acute Eye Irritation/Corrosion, Adopted by the Council on April 2002
- EPA Office of Prevention, Pesticides and Toxic Substances (OPPTS), Health Effects Test Guidelines:

1

- Guideline #870.2400, Acute Eye Irritation, effective August 1998
- o Guideline #870.2500, Acute Dermal Irritation, effective August 1998
- Guideline #870.1200, Acute Dermal Toxicity, effective August 1998
- FHSA Federal Hazardous Substance Act
  - o 16 CFR 1500.40, Acute Dermal Toxicity
  - 16 CFR 1500.41, Primary Dermal Irritation
  - 16 CFR 1500.42, Primary Eye Irritation

(b)(6), (b)(7)(c)

Millennium BioResearch Inc., (dba/MB Research Laboratories)

\\192.168.5.50\t\tdrive\bwc-docs\winword\usda\annual report-col e -2006.doc